Mineralocorticoid Receptor Deficiency in T Cells Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction Through Modulating T-Cell Activation

Hypertension

Volumn 70, Issue 1, 2017, Pages 137-147

  Li, Chao ^a,b,c   Sun, Xue Nan ^a,b,c   Zeng, Meng Ru ^a,b,c   Zheng, Xiao Jun ^a,b,c   Zhang, Yu Yao ^a,b,c   Wan, Qiangyou ^c   Zhang, Wu Chang ^a,b   Shi, Chaoji ^b   Du, Lin Juan ^a,b,c   Ai, Tang Jun ^a,b,c   Liu, Yuan ^a,b,c   Liu, Yan ^a,b   Du, Li Li ^a,b   Yi, Yi ^a   Yu, Ying ^d   Duan, Sheng Zhong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cardiac hypertrophy; heart failure; mineralocorticoid receptor; T cells; T cell activation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CD69 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; EPLERENONE; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN HEAVY CHAIN BETA; NATRIURETIC PEPTIDE A; NATRIURETIC PEPTIDE B; RANTES; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ABDOMINAL AORTIC CONSTRICTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC CONSTRICTION; ARTICLE; CARDITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; AORTA; CARDIOMEGALY; HEART FAILURE; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; AORTA; CARDIOMEGALY; HEART FAILURE; MICE; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; T-LYMPHOCYTES;

EID: 85020153208     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.09070     Document Type: Article

References (45)

1. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245-262. doi: 10.1016/j. yjmcc.2016.06.001.
2. Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133:447-454. doi: 10.1161/CIR.0000000000000366.
3. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131:1019-1030. doi: 10.1161/CIRCULATIONAHA.114.008788.
4. Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res. 2015;116:354-367. doi: 10.1161/CIRCRESAHA.116.304072.
5. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. 2015;8:776-787. doi: 10.1161/ CIRCHEARTFAILURE.115.002225.
6. Wang H, Kwak D, Fassett J, Hou L, Xu X, Burbach BJ, Thenappan T, Xu Y, Ge JB, Shimizu Y, Bache RJ, Chen Y. CD28/B7 deficiency attenuates systolic overload-induced congestive heart failure, myocardial and pulmonary inflammation, and activated T cell accumulation in the heart and lungs. Hypertension. 2016;68:688-696. doi: 10.1161/ HYPERTENSIONAHA.116.07579.
7. Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C, Delage C, Calise D, Dutaur M, Parini A, Pizzinat N. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129:2111-2124. doi: 10.1161/ CIRCULATIONAHA.113.007101.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi: 10.1056/ NEJM199909023411001.
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi: 10.1056/NEJMoa030207.
10. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.
11. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427. doi: 10.1161/01.CIR.0000153800.09920.40.
12. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664. doi: 10.1161/01. HYP.0000203772.78696.67.
13. Pitt B. Heart failure: the role for mineralocorticoid receptor antagonists. Swiss Med Wkly. 2014;144:w13959. doi: 10.4414/smw.2014.13959.
14. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400-408. doi: 10.1161/ CIRCULATIONAHA.110.983023.
15. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011;57:746-754. doi: 10.1161/HYPERTENSIONAHA. 110.163287.
16. Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN, Yang QZ, Ma SM, Huang B, Berger S, Wang W, Wu Y, Yu Y, Duan SZ, Mortensen RM. Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One. 2014;9:e110950. doi: 10.1371/journal.pone.0110950.
17. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-3364. doi: 10.1172/ JCI41080.
18. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-543. doi: 10.1161/ HYPERTENSIONAHA.109.131110.
19. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM, Young MJ. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012;153:3416-3425. doi: 10.1210/ en.2011-2098.
20. Sun XN, Li C, Liu Y, et al. T cell mineralocorticoid receptor controls blood pressure by regulating interferon gamma. Circ Res. 2017. pii: CIRCRESAHA.116.310480. doi: 10.1161/CIRCRESAHA.116.310480. [Epub ahead of print].
21. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y, Komuro I. Calcineurin plays a critical role in the development of pressure overloadinduced cardiac hypertrophy. Circulation. 2001;104:97-101.
22. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381.
23. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Mortensen RM. Direct monitoring pressure overload predicts cardiac hypertrophy in mice. Physiol Meas. 2007;28:1329-1339. doi: 10.1088/0967-3334/ 28/11/001.
24. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius FC 3rd, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, Mortensen RM. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest. 2007;117:812-822. doi: 10.1172/ JCI28859.
25. Ayuzawa N, Nagase M, Ueda K, Nishimoto M, Kawarazaki W, Marumo T, Aiba A, Sakurai T, Shindo T, Fujita T. Rac1-mediated activation of mineralocorticoid receptor in pressure overloadinduced cardiac injury. Hypertension. 2016;67:99-106. doi: 10.1161/ HYPERTENSIONAHA.115.06054.
26. Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10:e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688.
27. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763. doi: 10.1146/annurev. immunol.22.012703.104702.
28. Itani HA, Xiao L, Saleh MA, et al. CD70 exacerbates blood pressure elevation and renal damage in response to repeated hypertensive stimuli. Circ Res. 2016;118:1233-1243. doi: 10.1161/CIRCRESAHA. 115.308111.
29. Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159-176. doi: 10.1161/ CIRCRESAHA.116.308030.
30. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2016;67:2050-2060. doi: 10.1016/j.jacc.2016.01.073.
31. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591-619. doi: 10.1146/annurev. immunol.021908.132706.
32. Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol. 1996;3:301-304.
33. Fazekas de St Groth B, Smith AL, Higgins CA. T cell activation: In vivo veritas. Immunol Cell Biol. 2004;82:260-268.
34. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472-484. doi: 10.1038/ nri1632.
35. Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, May MJ, Zhu Y, Lutz M, Collins S, Dehoff M, Kang S, Whartenby K, Powell J, Leahy D, Worley PF. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science. 2008;319:476-481. doi: 10.1126/science.1151227.
36. Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM, Young MJ. Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension. 2012;60:1443-1450. doi: 10.1161/HYPERTENSIONAHA.112.203158.
37. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/ salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension. 2014;63:1033-1040. doi: 10.1161/ HYPERTENSIONAHA.113.01803.
38. Montes-Cobos E, Li X, Fischer HJ, Sasse A, Kügler S, Didié M, Toischer K, Fassnacht M, Dressel R, Reichardt HM. Inducible knock-down of the mineralocorticoid receptor in mice disturbs regulation of the reninangiotensin-aldosterone system and attenuates heart failure induced by pressure overload. PLoS One. 2015;10:e0143954. doi: 10.1371/journal. pone.0143954.
39. Casares S, Stan AC, Bona CA, Brumeanu TD. Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II-peptide chimera. Nat Biotechnol. 2001;19:142-147. doi: 10.1038/84404.
40. Besedovsky L, Linz B, Born J, Lange T. Mineralocorticoid receptor signaling reduces numbers of circulating human naïve T cells and increases their CD62L, CCR7, and CXCR4 expression. Eur J Immunol. 2014;44:1759-1769. doi: 10.1002/eji.201344265.
41. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension. 2014;63:797-803. doi: 10.1161/ HYPERTENSIONAHA.113.02883.
42. Herrada AA, Contreras FJ, Marini NP, Amador CA, González PA, Cortés CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, Fardella CE, Kalergis AM. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184:191-202. doi: 10.4049/ jimmunol.0802886.
43. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914-920. doi: 10.1038/ nm.1964.
44. Hayward SL, Bautista-Lopez N, Suzuki K, Atrazhev A, Dickie P, Elliott JF. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice. J Immunol. 2006;176:7715-7725.
45. Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ, Du J. Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS One. 2012;7:e35506. doi: 10.1371/journal.pone.0035506.